ClinicalTrials.Veeva

Menu

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer (PORTICO-SABR)

C

CCTU- Cancer Theme

Status

Unknown

Conditions

Cancer of Pancreas

Treatments

Radiation: Pre-operative stereotactic ablative body radiotherapy

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04128332
PORTICO-SABR

Details and patient eligibility

About

A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.

Full description

This is a single-centre, prospective, non-randomised feasibility study. This study will assess whether SABR can safely be given immediately prior to Whipple's resection by assessing the rate of post-operative complications.

Enrollment

10 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Stage 1:

  • Have given written informed consent to participate in stage 1
  • Be aged 16 years or over at the time of signing the informed consent form
  • Presence of a hypodense pancreatic mass on contrast enhanced CT scan highly suspicious of operable primary pancreatic cancer as assessed by a pancreatic multi-disciplinary team (MDT)
  • Have not had pre-operative systemic therapy or radiotherapy

Inclusion Criteria Stage 2:

  • Have participated in stage 1 of the study
  • Have confirmed histological or cytological diagnosis of primary pancreatic adenocarcinoma OR radiological evidence of pancreatic head mass with supportive cytological or histological findings.
  • Be scheduled to undergo pancreatico-duodenectomy (Whipple's) resection.
  • Written informed consent to participate in stage 2
  • Aged 16 years or over at the time of signing informed consent
  • Have not had pre-operative systemic therapy or radiotherapy
  • ECOG Performance status 0-1
  • Adequate renal function: GFR ≥ 60

Exclusion Criteria:

  • Any condition or abnormalities that in the judgement of the investigator/surgeon/clinical oncologist would place the patient at undue risk
  • Women who are known to be pregnant
  • Previous abdominal radiotherapy
  • Women of child-bearing potential who are unwilling to use 2 highly effective forms of contraception during the study treatment period

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Stereotactic ablative radiotherapy (SABR)
Other group
Description:
Stereotactic ablative radiotherapy (SABR) delivering 35Gy in five fractions (7Gy/fraction) over 5 days.
Treatment:
Radiation: Pre-operative stereotactic ablative body radiotherapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems